Intellia Therapeutics Inc Stock
There is an upward development for Intellia Therapeutics Inc compared to yesterday, with an increase of €0.21 (2.180%).
Currently there is a rather positive sentiment for Intellia Therapeutics Inc with 26 Buy predictions and 5 Sell predictions.
With a target price of 24 € there is potential for a 143.9% increase which would mean more than doubling the current price of 9.84 € for Intellia Therapeutics Inc.
Our community identified positive and negative aspects for Intellia Therapeutics Inc stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Intellia Therapeutics Inc stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 2.180% | -1.332% | -35.020% | -10.751% | 23.367% | -74.935% | -91.945% |
| Chromadex Corp | 2.880% | -1.429% | 0.000% | -66.341% | -49.818% | 84.000% | -62.192% |
| Cardio3 Biosciences S.A. | -0.860% | 10.952% | 21.354% | -37.197% | 72.593% | -52.254% | -93.076% |
| Polynovo Ltd | 3.390% | -10.095% | -7.451% | -32.571% | -30.588% | -49.519% | -65.797% |
Comments
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $49.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its price target lowered by HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
News
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
An exciting new CRISPR-based tool is making waves in the scientific literature this spring. Because the new technology destroys targeted diseased cells outright rather than editing their genetic
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
Intellia Therapeutics (NASDAQ: NTLA) has been on fire this year. Shares of the clinical-stage biotech have climbed an impressive 83% to date. However, Wall Street remains bullish on the company
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Choosing between Intellia Therapeutics (NASDAQ:NTLA) and Omeros (NASDAQ:OMER) in 2026 requires balancing the explosive potential of gene editing against the steady rollout of newly approved orphan